Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.53 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GRM8 | O00222 | 1/20 | 0.46 |
| ▸ | GRM6 | O15303 | 1/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26641058 | 1.00 | ALDH1A1 (0.54) | ALDH1A1MAPTSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL26641062 | 1.00 | ALDH1A1 (0.54) | ALDH1A1MAPTSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL29814950 | 0.96 | ALDH1A1 (0.55) | ALDH1A1MAPTSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL29814995 | 0.96 | ALDH1A1 (0.55) | ALDH1A1MAPTSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL29814701 | 0.91 | SLC1A3 (0.56) | ALDH1A1MAPTSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL29814907 | 0.91 | SLC1A3 (0.56) | ALDH1A1MAPTSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL14615873 | 0.84 | ALDH1A1 (0.63) | ALDH1A1SLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL3448866 | 0.84 | ALDH1A1 (0.63) | ALDH1A1SLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL3449699 | 0.83 | ALDH1A1 (0.55) | ALDH1A1SLC1A3SLC1A2SLC1A1CA2 | |
| SCHEMBL9497964 | 0.83 | ALDH1A1 (0.55) | ALDH1A1SLC1A3SLC1A2SLC1A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4440592-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Zealand Pharma A/S (DK) | 2024-10-09 | — | — | EP | claimed |
| WO-2023099669-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | ZEALAND PHARMA A/S (DK) | 2023-06-08 | — | — | WO | claimed |
| WO-2025091122-A1 | CYCLIC PEPTIDE ANALOGS OF MELANOCORTIN AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2025-05-08 | — | — | WO | disclosed |
| EP-4504732-A2 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | University of Connecticut (US) | 2025-02-12 | — | — | EP | disclosed |
| EP-4499663-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | Provincial Health Services Authority (CA) | 2025-02-05 | — | — | EP | disclosed |
| EP-4440592-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Zealand Pharma A/S (DK) | 2024-10-09 | — | — | EP | disclosed |
| EP-4422695-A1 | METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | Araris Biotech AG (CH) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023192975-A2 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023178449-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2023-09-28 | — | — | WO | disclosed |
| EP-4232095-A1 | MEANS AND METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | Araris Biotech AG (CH) | 2023-08-30 | — | — | EP | disclosed |
| EP-4228707-A1 | NANOMATERIAL AND METHODS OF USE THEREOF | University of Connecticut (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023099669-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | ZEALAND PHARMA A/S (DK) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023072934-A1 | METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | ARARIS BIOTECH AG (CH) | 2023-05-04 | — | — | WO | disclosed |
| US-11395857-B2 | Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2022-07-26 | — | — | US | disclosed |
| WO-2022084560-A1 | MEANS AND METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | ARARIS BIOTECH AG (CH) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022081721-A1 | NANOMATERIAL AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11395857-B2 | Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy | MC1R, MC5R, MC3R | ALDH1A1 3276/4885MAPT 3960/4885SLC1A3 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.